

Medication Adherence in Chronic Illnesses: Barriers, Outcomes, and Pharmacist-Led Strategies

Vidhee Pawar^{1*}, Jewelleisa Pepiya¹, Aditi Yadav¹, Kinjal Patel²

¹Student, K.B. Raval College of Pharmacy, Shertha, Gandhinagar, Gujarat 382423, India

²Professor, Department of Pharmacognosy, K.B. Raval College of Pharmacy, Shertha Gandhinagar, Gujarat 382423, India

*Correspondence:

Vidhee Pawar

K.B. Raval College of Pharmacy,

Shertha, Gandhinagar,

Gujarat 382423, India

Email Id: pawarvidhee9@gmail.com

ABSTRACT

Medication adherence is a cornerstone of effective management of chronic illnesses such as diabetes, cardiovascular diseases, asthma, chronic obstructive pulmonary disease, hypertension, and chronic kidney disease. Despite major advances in pharmacotherapy, suboptimal adherence remains a persistent global challenge, with nearly half of patients failing to take medications as prescribed. Poor adherence leads to disease progression, avoidable hospitalizations, reduced quality of life, and increased healthcare expenditure. This review explores the multidimensional concept of medication adherence, examines patient, therapy, healthcare system-, and socio-economic-related barriers, and discusses the clinical and economic outcomes of non-adherence. Particular emphasis is placed on pharmacist-led interventions, including medication therapy management, patient education, motivational interviewing, digital health integration, and collaborative care models. Evidence suggests that pharmacists play a pivotal role in improving adherence and optimizing therapeutic outcomes. Future directions focusing on personalized medicine, artificial intelligence, and integrated healthcare systems are also discussed. Strengthening adherence strategies through pharmacist involvement remains essential for sustainable chronic disease management.

Keywords: Medication adherence, chronic disease, pharmacist intervention, non-adherence, healthcare outcomes, pharmaceutical care.

INTRODUCTION

Chronic diseases are the leading cause of mortality and disability worldwide, accounting for approximately 74% of global deaths.¹ Conditions such as diabetes mellitus, cardiovascular disease, asthma, chronic obstruction pulmonary diseases, hypertension, and chronic kidney disease require lifelong pharmacotherapy to maintain disease control and prevent complications. However, the effectiveness of treatment depends not only on drug efficacy but also on patient's adherence to prescribed regimens.²

Medication adherence is defined as the extent to which a patient's medication taking behavior corresponds with agreed recommendations from a healthcare provider.³ The World Health Organization has emphasized that improving adherence may have a greater impact on population health than the development of new

medicines.⁴ Despite this, adherence rates for chronic diseases average only about 50% in developed countries and are even lower in developing regions.⁵

Non-adherence contributes to therapeutic failure, increased hospitalization, disease progression, and mortality.⁶ Additionally, it imposes a significant economic burden, with costs exceeding billions annually due to avoidable complications and resource utilization.⁷ The causes of non-adherence are complex and multifactorial, involving patient beliefs, medication complexity, health literacy, healthcare access, and socio-economic factors.⁸

Pharmacists, as accessible healthcare professionals, are uniquely positioned to influence medication use behaviour. Their involvement in counselling, monitoring, medication therapy management, and collaborative care has demonstrated improvements in adherence and patient outcomes.⁹ This review aims to analyse barriers to medication adherence in chronic illness, assess the clinical and economic consequences, and highlight pharmacist led strategies to enhance adherence and optimize therapy.

CONCEPT OF MEDICATION ADHERENCE

Medication adherence encompasses three interrelated phases: initiation, implementation, and persistence.¹⁰ Initiation refers to when the patient takes the first dose, implementation describes how the dosing corresponds to the prescribed regimen, and persistence reflects the duration of therapy before discontinuation.

Traditionally, terms such as compliance and concordance were used; however, adherence emphasizes patient autonomy and shared decision making.¹¹ In chronic illnesses, adherence is influenced by continuous behavioural processes rather than single acts.

Measurement of adherence includes direct methods (drug concentration monitoring, directly observed therapy) and indirect methods (pill counts, refill records, electronic monitoring, and self-report questionnaires such as Morisky Medication Adherence Scale).¹² Each method has advantages and limitations, and often a combination is used in practice.

Understanding adherence behaviour requires considering psychological, social, and health system factors. Patient's perceptions of illness severity, medication necessity, fear of adverse effects, and cultural beliefs strongly affect adherence.¹³

BARRIERS TO MEDICATION ADHERENCE

Medication non-adherence is multifactorial and may be intentional or unintentional. Barriers can be categorized into patient related, therapy related, condition related, healthcare system related, and socio-economic factors.

Patient-Related Barriers

Patient related factors include forgetfulness, low health literacy, cognitive impairment, depression, lack of motivation, and negative beliefs about medications.¹⁴ Many patients discontinue therapy once symptoms improve, misunderstanding the chronic nature of their disease.

Psychological distress and poor patient provider communication further contribute to non-adherence.¹⁵ In elderly populations, visual impairment and memory decline significantly affect correct medication use.

Therapy-Related Barriers

Complex regimens, poly-pharmacy, frequent dosing, side effects, and long treatment duration reduce adherence.¹⁶ Patients with chronic diseases often receive multiple medications, increasing pill burden and confusion.

Adverse drug reactions, fear of dependency, and perceived inefficacy also discourage adherence.¹⁷

Condition Related Barriers

Asymptomatic diseases such as hypertension or hyper lipidemia often show poor adherence because patients do not perceive immediate benefits.¹⁸ Conversely, fluctuating symptoms may mislead patients to alter doses independently.

Comorbidities also complicate treatment and increase non-adherence risk.¹⁹

Healthcare System Related Barriers

Limited access to care, short consultation time, fragmented services, lack of follow-up, and inadequate patient education contribute to non-adherence.²⁰ Poor coordination among healthcare providers can result in inconsistent messages and therapeutic duplication.

Socio-Economic Barriers

Medication cost, transportation issues, social support, employment constraints, and cultural beliefs influence adherence.²¹ Financial barriers remain one of the most significant predictors of non-adherence globally.

Table 1. Major Barriers to Medication Adherence

Category	Examples
Patient-related	Forgetfulness, beliefs, depression
Therapy-related	Polypharmacy, side effects, dosing frequency
Condition-related	Asymptomatic disease, comorbidities
System-related	Poor follow-up, limited access
Socio-economic	Cost, literacy, social support

OUTCOMES OF MEDICATION NON-ADHERENCE

Non-adherence leads to serious clinical, humanistic, and economic consequences.

Clinical Outcomes

Poor adherence increases disease progression, complications, and mortality.²² In diabetes, non-adherence results in poor glycemic control and microvascular complications. In cardiovascular diseases, it increases stroke, myocardial infarction, and hospitalization rates.²³

Asthma and chronic obstruction pulmonary disease patients with low adherence experience more exacerbations and emergency visits.²⁴

Humanistic Outcomes

Medication non-adherence negatively impacts quality of life, functional status, and patient satisfaction.²⁵ Anxiety and frustration increase when therapy fails due to improper medication use rather than drug inefficacy.

Economic Outcomes

Non-adherence accounts for avoidable healthcare costs through hospital admissions, extended therapy, and loss of productivity.²⁶ Estimates suggest that non-adherence costs healthcare systems hundreds of billions of dollars annually worldwide.²⁷




Fig. 1: Impact Pathway of Medication Non-Adherence²⁴⁻²⁵

PHARMACIST LED STRATEGIES TO IMPROVE ADHERENCE

Pharmacists play a critical role in promoting rational medication use. Their interventions target patient education, regimen simplification, behavioural support, and monitoring.²⁸

Medication Therapy Management (MTM)

Medication therapy management involves comprehensive medication review, identification of drug-related problems, patient counselling, and follow-up.²⁸ Medication therapy management improves therapeutic outcomes, reduces adverse events, and enhances adherence in chronic conditions.

Patient Education and Counselling

Pharmacist counselling improves understanding of disease, medication purpose, dosing, and side effects.²⁹ Individualized education empowers patients and increases confidence in therapy.

Motivational Interviewing

Motivational interviewing addresses ambivalence and enhances intrinsic motivation for adherence.³⁰ Pharmacists trained in behavioural techniques help patients overcome intentional non-adherence.

Regimen Simplification

Reducing dosing frequency, fixed-dose combinations, and synchronization of refills improve adherence.³¹ Pharmacists collaborate with prescribers to optimize regimens.

Digital Health and Technology

Electronic reminders, mobile applications, tele-pharmacy, and smart pill bottles enhance monitoring and patient engagement.³² Pharmacists integrating digital tools show significant adherence improvements.

Collaborative Care Models

Inter professional collaboration among physicians, nurses, and pharmacists improves chronic disease outcomes.³³ Pharmacist inclusion in healthcare teams reduces medication errors and improves continuity of care.



Fig. 2:

Pharmacist-Led Interventions to Improve Medication Adherence³²⁻³³

Table 2. Pharmacist Interventions and Outcomes

Intervention	Outcome
Medication Therapy Management	Improved adherence, reduced Adverse drug effect
Counselling	Better disease understanding
Motivational interviewing	Behavioural change
Digital tools	Improved persistence
Collaborative care	Reduced hospitalization

ROLE OF PHARMACISTS IN SPECIFIC CHRONIC DISEASES

In diabetes, pharmacists improve glycaemic control and adherence through education and monitoring.³⁴ In hypertension, pharmacist interventions reduce blood pressure significantly.³⁵ In asthma and chronic obstruction pulmonary diseases, inhaler technique training improves symptom control and reduces exacerbations.³⁶

Similarly, in cardiovascular diseases, pharmacist-managed clinics improve lipid profiles and adherence.³⁷



Fig. 3: Role of Pharmacists in Specific Chronic Diseases³⁷⁻³⁸

FUTURE DIRECTIONS

Future adherence strategies will integrate personalized medicine, artificial intelligence, and real-time monitoring.³⁸ Pharmacogenomics may guide individualized regimens, while Artificial intelligence based adherence prediction models could allow early intervention.³⁹

Expanding tele-pharmacy and community based services will further strengthen adherence support systems.⁴⁰

CONCLUSION

Medication adherence remains a major challenge in chronic disease management. Barriers are multifactorial and require multidisciplinary solutions. Pharmacists, through education, Medication Therapy Management, behavioural interventions, and digital integration, significantly improve adherence and therapeutic outcomes. Strengthening pharmacist led strategies within healthcare systems is essential for sustainable, patient-centred chronic care.

CONFLICT OF INTEREST: The authors declare that there are no conflicts of interest regarding the publication of this paper.

REFERENCES

1. World Health Organization. Non-communicable diseases. Geneva: World Health Organization; 2023.
2. Sabaté E. Adherence to long-term therapies: evidence for action. Geneva: World Health Organization; 2003.
3. Vrijens B, De Geest S, Hughes DA, Przemyslaw K, Demonceau J, Ruppar T, et al. A new taxonomy for describing and defining adherence to medications. *Br J Clin Pharmacol.* 2012;73(5):691–705.
4. World Health Organization. Adherence to long-term therapies: evidence for action. Geneva: WHO; 2003.
5. Brown MT, Bussell JK. Medication adherence: WHO cares? *Mayo Clin Proc.* 2011;86(4):304–314.
6. Osterberg L, Blaschke T. Adherence to medication. *N Engl J Med.* 2005;353(5):487–497.

7. Cutler RL, Fernandez-Llimos F, Frommer M, Benrimoj C, Garcia-Cardenas V. Economic impact of medication non-adherence by disease groups: a systematic review. *Patient Prefer Adherence*. 2018;12:1323–1336.
8. Kardas P, Lewek P, Matyjaszczyk M. Determinants of patient adherence: a review of systematic reviews. *Front Pharmacol*. 2013;4:91.
9. Chisholm-Burns MA, Lee JK, Spivey CA, Slack M, Herrier RN, Hall-Lipsy E, et al. US pharmacists' effect as team members on patient care: systematic review and meta-analyses. *Med Care*. 2010;48(10):923–933.
10. Vrijens B, Antoniou S, Burnier M, de la Sierra A, Volpe M. Current situation of medication adherence in hypertension. *Eur Heart J*. 2017;38(15):1148–1157.
11. Horne R, Chapman SCE, Parham R, Freemantle N, Forbes A, Cooper V. Understanding patients' adherence-related beliefs about medicines prescribed for long-term conditions: a meta-analytic review. *PLoS Med*. 2013;10(12):e1001422.
12. Lam WY, Fresco P. Medication adherence measures: an overview. *Biomed Res Int*. 2015;2015:217047.
13. DiMatteo MR. Variations in patients' adherence to medical recommendations: a quantitative review. *Med Care*. 2004;42(3):200–209.
14. Jin J, Sklar GE, Min Sen Oh V, Chuen Li S. Factors affecting therapeutic compliance: a review from the patient's perspective. *Drugs*. 2008;68(3):269–286.
15. Kvarnstrom K, Airaksinen M, Liira H. Barriers and facilitators to medication adherence: a qualitative study with general practitioners. *Int J Clin Pharm*. 2018;40(1):146–154.
16. Ingersoll KS, Cohen J. The impact of medication regimen factors on adherence to chronic treatment: a review of literature. *Clin Psychol Rev*. 2008;28(2):229–245.
17. Rolnick SJ, Pawloski PA, Hedblom BD, Asche SE, Bruzek RJ. Patient characteristics associated with medication adherence. *Patient Prefer Adherence*. 2013;7:335–344.
18. Burnier M. Medication adherence and persistence as the cornerstone of effective antihypertensive therapy. *Hypertension*. 2006;48(2):203–209.
19. Tinetti ME, Bogardus ST, Agostini JV. Potential pitfalls of disease-specific guidelines for patients with multiple conditions. *JAMA*. 2004;292(6):716–724.
20. Nieuwlaat R, Wilczynski N, Navarro T, Hobson N, Jeffery R, Keenanasseril A, et al. Interventions for enhancing medication adherence. *Cochrane Database Syst Rev*. 2014;(11):CD000011.
21. Piette JD, Heisler M, Wagner TH. Cost-related medication underuse among chronically ill adults. *Diabetes Care*. 2004;27(2):384–391.
22. Ho PM, Rumsfeld JS, Masoudi FA, McClure DL, Plomondon ME, Steiner JF, et al. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. *Arch Intern Med*. 2006;166(17):1836–1841.
23. Rasmussen JN, Chong A, Alter DA. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. *BMJ*. 2007;335(7623):915.
24. Williams LK, Peterson EL, Wells K, Ahmedani BK, Kumar R, Burchard EG, et al. Quantifying the proportion of severe asthma exacerbations attributable to inhaled corticosteroid nonadherence. *J Allergy Clin Immunol*. 2004;114(6):1288–1293.
25. Cleemput I, Kesteloot K, DeGeest S. A review of the literature on the economics of noncompliance. *Pharmacoeconomics*. 2002;20(13):871–882.
26. Iuga AO, McGuire MJ. Adherence and health care costs. *Risk Manag Healthc Policy*. 2014;7:35–44.
27. Cutler DM, Everett W. Thinking outside the pillbox—medication adherence as a priority for health care reform. *Health Aff (Millwood)*. 2010;29(3):304–310.
28. Bluml BM. Definition of medication therapy management: development of professionwide consensus. *J Am Pharm Assoc*. 2005;45(5):566–572.
29. Puspitasari HP, Aslani P, Krass I. A review of counseling practices on chronic disease management. *Res Social Adm Pharm*. 2013;9(1):e83–e95.
30. Rollnick S, Miller WR, Butler CC. *Motivational interviewing in health care: helping patients change behavior*. New York: Guilford Press; 2008.
31. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. *Clin Ther*. 2001;23(8):1296–1310.

32. Thakkar J, Kurup R, Laba TL, Santo K, Thiagalingam A, Rodgers A, et al. Mobile telephone text messaging for medication adherence in chronic disease. *JAMA Intern Med.* 2016;176(3):340–349.
33. Carter BL, Rogers M, Daly J, Zheng S, James PA. The potency of team-based care interventions for hypertension. *Arch Intern Med.* 2009;169(19):1748–1755.
34. Machado M, Bajcar J, Guzzo GC, Einarson TR. Sensitivity of patient outcomes to pharmacist interventions. *Ann Pharmacother.* 2007;41(10):1569–1577.
35. Santschi V, Chiolero A, Burnand B, Colosimo AL, Paradis G. Impact of pharmacist care in the management of cardiovascular disease risk factors. *J Am Heart Assoc.* 2014;3(2):e000718.
36. Basheti IA, Armour CL, Reddel HK, Bosnic-Anticevich SZ. Long-term maintenance of pharmacists' inhaler technique demonstration skills. *Respir Med.* 2007;101(5):994–1001.
37. Clifford RM, Davis WA, Batty KT, Davis TM. Effect of a pharmaceutical care program on vascular risk factors in type 2 diabetes. *Ann Pharmacother.* 2005;39(9):1584–1590.
38. Demonceau J, Ruppert T, Kristanto P, Hughes DA, Fargher E, Kardas P, et al. Identification and assessment of adherence-enhancing interventions. *BMJ Open.* 2013;3(1):e001901.
39. Kini V, Ho PM. Interventions to improve medication adherence: a review. *Circulation.* 2018;138(4):463–465.
40. Totten AM, Womack DM, Eden KB, McDonagh MS, Griffin JC, Grusing S, et al. *Telehealth: mapping the evidence for patient outcomes from systematic reviews.* Rockville (MD): Agency for Healthcare Research and Quality; 2016.



IJRTI